What are the best centers for treatment and research on Alzheimer disease?

Best Centers for Alzheimer's Disease Treatment and Research

Seek care at specialized Alzheimer's Disease Centers (ADCs) or Comprehensive Alzheimer's Disease Centers (CADCs) that are part of the National Institute on Aging network, which provide integrated diagnostic capabilities, access to disease-modifying therapies, and participation in clinical trials.

Why Specialized Centers Matter

The landscape of Alzheimer's disease has fundamentally changed with FDA-approved amyloid-lowering therapies (lecanemab, donanemab). Treatment with these disease-modifying monoclonal antibodies requires high proficiency and comprehensive multidisciplinary teams 1. Not all healthcare facilities have the infrastructure, expertise, or resources to safely administer these therapies and monitor for serious side effects like ARIA (amyloid-related imaging abnormalities).

Key Features to Look For

Essential Capabilities

• Comprehensive diagnostic services in one location ("one-stop shop" model) including:

  • Advanced biomarker testing (amyloid PET, CSF assays, emerging blood-based biomarkers)
  • MRI capabilities for ARIA monitoring
  • Neuropsychological testing
  • Genetic counseling for APOE testing 1

• Multidisciplinary teams including:

  • Neurologists specializing in dementia
  • Advanced practice providers (APPs) trained in AD care
  • Memory-care experienced nurses
  • Genetic counselors
  • Infusion specialists 1, 2

• Clinical trial access: Centers participating in AD clinical trials offer access to cutting-edge therapies before they become widely available 3

Specific Center Models

National Institute on Aging Alzheimer's Disease Centers (ADCs): Since 1978, the NIH has established an extensive national network of ADCs at academic institutions. These centers have evolved into CADCs that integrate research, clinical care, education, and clinical trials 4. They maintain large patient cohorts with comprehensive biospecimen repositories (brain tissue, CSF, blood, DNA) 5.

Specialized Anti-Amyloid Treatment Clinics: Newer models like dedicated anti-amyloid treatment clinics provide streamlined workflows specifically designed for patients receiving monoclonal antibody therapies, with APP-led evaluation and shared decision-making 2.

Hub-and-Spoke Models: Given the shortage of dementia specialists, leading centers are developing collaborative networks connecting specialty centers with community primary care providers to expand access 1.

Geographic Considerations

While the evidence doesn't rank specific institutions, look for:

• Academic medical centers with NIA-designated ADC status
• Centers participating in the Alzheimer's Disease Cooperative Study (ADCS)
• Institutions with established biorepositories and research programs 5
• Healthcare systems that have developed specialized AD treatment pathways 2, 6

Critical Timing Factor

Early referral is essential. The new disease-modifying therapies are only FDA-approved for mild cognitive impairment (MCI) or mild dementia stages of AD 1. Waiting until moderate or severe dementia develops eliminates treatment eligibility. Centers with capabilities for early detection through biomarker testing are particularly valuable 6, 7.

Common Pitfalls to Avoid

• Delaying evaluation: Memory concerns should prompt immediate specialist referral, not watchful waiting
• Choosing centers without biomarker capabilities: Accurate AD diagnosis now requires amyloid confirmation via PET or CSF testing 1
• Overlooking clinical trial opportunities: Trial participation may provide access to therapies years before commercial availability 3
• Selecting facilities without ARIA monitoring infrastructure: MRI monitoring is mandatory for safety with monoclonal antibody therapies 1

Practical Access Strategy

1. Contact the Alzheimer's Association for referrals to nearby ADCs or specialized centers
2. Verify the center offers:
   • Same-day comprehensive diagnostic evaluation
   • Amyloid biomarker testing (PET or CSF)
   • Access to FDA-approved disease-modifying therapies
   • Active clinical trial enrollment
3. Ask about wait times: Some centers have capacity constraints given overwhelming demand 1
4. Confirm insurance coverage: CMS now covers amyloid PET and approved therapies when patients are registered in approved registries 1

The healthcare system is actively working to scale capacity through new partnerships between academic centers, community organizations, and primary care networks 1, 6. However, specialized centers with established AD programs remain the gold standard for comprehensive evaluation and access to the full range of treatment options.